Lipiclair (Fenofibrate)

Fenofibrate activates the nuclear receptor PPARα, which regulates genes involved in fatty‑acid oxidation and lipoprotein metabolism. Activation leads to increased breakdown of triglyceride‑rich particles, reduced VLDL synthesis, and enhanced HDL production, thereby improving the overall lipid profile.

The specific dose of Lipiclair is determined by the prescribing clinician based on the patient’s lipid levels, renal function, and overall health status. Physicians follow established dosing guidelines for fenofibrate but individual regimens may vary.

Safety data for fenofibrate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Lipiclair, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to fenofibrate is the statin class, which primarily lowers LDL‑cholesterol. Fenofibrate is more effective at reducing triglycerides and raising HDL‑cholesterol, while statins are stronger LDL‑reducers. In some patients, a combination of both classes is used for comprehensive lipid management.

Lipiclair should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children.

Lipiclair is taken orally, usually once daily with a meal to enhance absorption. Patients should swallow the tablet whole with water and follow the dosing schedule prescribed by their healthcare provider.

The most serious risks include rhabdomyolysis (severe muscle breakdown), significant liver injury, and rare hypersensitivity reactions such as severe skin rash or angioedema. Patients should promptly report unexplained muscle pain, dark urine, jaundice, or any signs of an allergic reaction.

Lipiclair is contraindicated in patients with severe liver disease, active gallbladder disease, or known hypersensitivity to fenofibrate or any excipients. Caution is also advised for individuals with renal impairment or those taking medications that markedly increase the risk of myopathy.